[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Botkin Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100602469","studies-on-adsorption-international-learning-initiative-global-100602469",false,"NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[27,28,29,30,31,32,33,34],"CKD (Chronic Kidney Disease) Stage 5D","Uremia; Chronic","Uremic; Toxemia","Inflammation Chronic","Hemodialysis","Inflammation Biomarkers","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[36,37,38],"Program dialysis","Sorption","Complications of program dialysis","RECRUITING","2025-12-03",{"date":42,"type":43},"2025-12-10","ACTUAL",{"date":45,"type":43},"2025-06-01",{"date":47,"type":21},"2026-06-30",{"name":49,"class":50},"Botkin Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":51},"100597292","finerenone-in-patients-with-iga-nephropathy-prospective-interventional-trial-100597292","NCT07056595","Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial","Inclusion Criteria:\n\n* Adults (\\> 18 years) with the primary IgAN diagnosed by kidney biopsy;\n* Treatment with stable doses of iRAS or\u002Fand iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;\n* Blood pressure \\\u003C 140\u002F90 mm Hg\n* 24-hour urinary albumin excretion \\> 300 mg\n\nExclusion Criteria:\n\n* Kidney transplantation in medical history\n* Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;\n* Heart failure with ejection fraction \\\u003C40%;\n* Acute myocardial infarction and\u002For stroke less then 3 months before including in trial;\n* Presence ANCA in serum\n* Ongoing immunosuppressive treatment\n* eGFR \\\u003C 20 ml\u002Fmin\n* Pregnancy and breastfeeding\n* Uncontrolled blood pressure",{"count":59,"type":21},30,[24],": IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.",[63],"IgA Nephropathy (IgAN)","2025-06-30",{"date":66,"type":43},"2025-07-09",{"date":68,"type":43},"2025-05-21",{"date":70,"type":21},"2026-05-21",{"name":49,"class":50},""]